TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05106283

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep block and Combined Block
Description: Deep serratus anterior block and combined deep and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep block and Combined Block
Description: Deep serratus anterior block and combined deep and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
Study: NCT06184932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HAHE
Description: Participants will self-initiate rehabilitative activities through the HAHE program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergame
Description: Participants will self-initiate rehabilitative activities through the Exergame program.
Study: NCT06451978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature-based intervention
Description: The nature-based intervention is a manualised, caregiver-led intervention consisting of a physical manual comprising of 8 sessions of 8 different nature-based activities. It is designed for the person living with dementia or mild cognitive impairment and their caregiver to carry out the sessions together, either in their own home or out in a local area of nature.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nature-based intervention
Description: The nature-based intervention is a manualised, caregiver-led intervention consisting of a physical manual comprising of 8 sessions of 8 different nature-based activities. It is designed for the person living with dementia or mild cognitive impairment and their caregiver to carry out the sessions together, either in their own home or out in a local area of nature.
Study: NCT06147804

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical managment of Urinary bladder trauma after gynaecological and obstetric operation
Description: How to manage Urinary bladder trauma after gynaecological and obstetric operations by the best method to prevent the occurrnce of vesicouterine fistula
Study: NCT05232396

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-6R Monoclonal Antibody Injection 4mg/kg
Description: IL-6R Monoclonal Antibody Injection 4mg/kg i.v.,single use

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-6R Monoclonal Antibody Injection 6mg/kg
Description: IL-6R Monoclonal Antibody Injection 6mg/kg i.v. , single use

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-6R Monoclonal Antibody Injection 8mg/kg
Description: IL-6R Monoclonal Antibody Injection 8mg/kg i.v. , single use

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab Injection 8mg/kg
Description: Tocilizumab Injection 8mg/kg i.v., single use
Study: NCT06360133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVN001 Ophthalmic Solution, 5%
Description: VVN001 Ophthalmic Solution, 5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VVN001 Ophthalmic Solution, Vehicle
Description: VVN001 Ophthalmic Solution, Vehicle
Study: NCT06292689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardunolizumab
Description: 1. Not systematically treated:~   Cardunolizumab (10mg/kg) + Cisplatinum (50mg/m2)/ Carboplatinum (AUC 4-5) + Paclitaxel (175mg/m2) ± Bevacizumab (15mg/kg) for 6 cycles, every 3 weeks (Q3W), and then Cardunolizumab ± Bevacizumab Q3W maintenance treatment.~2. Previous systematic treatment:~Cardunolizumab (10mg/kg) + Chemotherapy regimen selected by the investigator ± Bevacizumab (15mg/kg) for 6 cycles, every 3 weeks (Q3W), and then Cardunolizumab ± Bevacizumab Q3W maintenance treatment.
Study: NCT05598359

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TA-65
Description: TA-65 is a purified small molecule extracted from Astragalus root

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive formulation
Study: NCT04713670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (A) T-V14
Description: vonoprazan(vocinti)-based triple therapy for 14 days (T-V14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (B) T-V7
Description: vonoprazan(vocinti)-based triple therapy for 7 days (T-V7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (C) D-V14
Description: vonoprazan(vocinti)-based dual therapy for 14 days (D-V14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (D) HD-V14
Description: vonoprazan(vocinti)-based high dose dual therapy for 14 days (HD-V14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (E) BQ-V14
Description: vonoprazan(vocinti)-based bismuth quadruple therapy for 14 days (BQ-V14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (F) RH-V14
Description: vonoprazan(vocinti)-based reverse hybrid therapy for 14 days (RH-V14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (G) BQ-L14
Description: lansoprazole(takepron)-based bismuth quadruple therapy for 14 days (BQ-L14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (H) T-L14
Description: lansoprazole(takepron)-based triple therapy for 14 days (T-L14)
Study: NCT04872478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX-2843
Description: MRX-2843 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX-2843
Description: MRX-2843 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX-2843
Description: MRX-2843 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX-2843
Description: MRX-2843 capsules
Study: NCT05881928

Intervention type: DRUG
Group type: OTHER
Intervention: Sodium Valproate 500 Mg Prolonged-Release Oral Tablet
Description: sodium valproate tablet30 mg / kg / day , maximum 1500mg / day . LTG :

Intervention type: DRUG
Group type: OTHER
Intervention: Lamotrigine
Description: lamotrigine tablet 0.5 mg/kg for 2 weeks in two divided doses , increased in 0.5mg/kg/day increments every 2weeks .

Intervention type: DEVICE
Group type: OTHER
Intervention: E.E.G
Description: device recording of brain activity. During this painless test, small sensors are attached to the scalp to pick up the electrical signals produced by the brain. These signals are recorded by a machine and are looked at by a doctoris
Study: NCT04872478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX-2843
Description: MRX-2843 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX-2843
Description: MRX-2843 capsules
Study: NCT04754022

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive Transfusion Strategy
Description: Patients will receive a RBC transfusion if their Hb concentration is \<75 g/L (\<7.5 g/dL; \<4.7mmol/L) intraoperatively and/or postoperatively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal transfusion strategy
Description: Patients will receive a RBC transfusion if their Hb concentration is \<95 g/L (\<9.5 g/dL; \<5.9mmol/L) intraoperatively, or postoperatively in the ICU; and/or \<85 g/L (\< 8.5 g/dL; \<5.3mmol/L) on the ward.
Study: NCT06477588

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Navigation
Description: Participants meet with Health Navigator twice in-person and receive 7 check-ins from the Health Navigator over a 6 month period. The health navigator provides participants with referrals and support to HIV, mental health, substance use, and other supportive services

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Navigation, Employment Navigation plus Contingency Management Intervention
Description: Participants meet with health navigator twice in-person and receive 7 check-ins from the health navigator over a 6 month period. The health navigator provides participants with referrals and support to HIV, mental health, substance use, and other supportive services. Participants meeting with the employment navigator twice in-person and receive 10 check-ins from the employment navigator over 12 months. The employment navigator provides participants with referrals to employment and career development opportunities in the community and up to $200 for employment and career development support (e.g., transportation to interview, GED preparation course). Participants also receive up to $140 for HIV/STI care, treatment, and prevention milestones as part of the contingency management interview over a period of 12 months.
Study: NCT06058585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone
Description: Finerenone 10mg or 20mg tablets, oral, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Finerenone
Description: Finerenone matched placebo tablets, oral, once daily
Study: NCT05831969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide: 10mg/d, 1-21d/28d orally; until disease progression or intolerable adverse reactions.
Study: NCT06197217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WPV01
Description: Subjects in the WPV01 group will receive WPV01 600mg orally (200mg, 3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in the Placebo group will receive WPV01 Placebo orally (3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments
Study: NCT04774315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: omalizumab 300mg SQ every 4 weeks as part of standard of care
Study: NCT05844774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPI (using HemoSphere) - guided algorithm
Description: Treatment of hypotension guided by the hypotension prediction index. Patients will receive treatment following the predetermined HPI-algorithm when the HPI exceeds 85%.

Intervention type: DEVICE
Group type: OTHER
Intervention: Treatment of hypotension following standard of care
Description: Patients receive standard of care treatment for hypotension, with a goal-mean arterial pressure (MAP) of 65mmHg.
Study: NCT04889079

Intervention type: BEHAVIORAL
Intervention: Contraceptive use (continuation/switching/discontinuation)
Description: Assessing contraceptive continuation/switching/discontinuation over 12-months

Intervention type: BEHAVIORAL
Intervention: Contraceptive use (continuation/switching/discontinuation)
Description: Assessing contraceptive continuation/switching/discontinuation over 12-months
Study: NCT05650905

Intervention type: DEVICE
Intervention: Dynamic Vessel Analyzer (DVA)
Description: Retinal neurovascular coupling, Retinal vessel diameters and Retinal oxygen saturation will be assessed using the DVA

Intervention type: DEVICE
Intervention: Dynamic Vessel Analyzer (DVA)
Description: Retinal neurovascular coupling, Retinal vessel diameters and Retinal oxygen saturation will be assessed using the DVA

Intervention type: DEVICE
Intervention: Dynamic Vessel Analyzer (DVA)
Description: Retinal neurovascular coupling, Retinal vessel diameters and Retinal oxygen saturation will be assessed using the DVA

Intervention type: DEVICE
Intervention: Fourier domain optical coherence tomography (FDOCT)
Description: Retinal blood velocities and Retinal blood flow will be assessed using the FDOCT

Intervention type: DEVICE
Intervention: Fourier domain optical coherence tomography (FDOCT)
Description: Retinal blood velocities and Retinal blood flow will be assessed using the FDOCT

Intervention type: DEVICE
Intervention: Fourier domain optical coherence tomography (FDOCT)
Description: Retinal blood velocities and Retinal blood flow will be assessed using the FDOCT

Intervention type: DEVICE
Intervention: Optical coherence tomography (OCT)
Description: Retinal nerve fiber layer thickness, Central retinal thickness and Retinal vessel density will be assessed using the OCT

Intervention type: DEVICE
Intervention: Optical coherence tomography (OCT)
Description: Retinal nerve fiber layer thickness, Central retinal thickness and Retinal vessel density will be assessed using the OCT

Intervention type: DEVICE
Intervention: Optical coherence tomography (OCT)
Description: Retinal nerve fiber layer thickness, Central retinal thickness and Retinal vessel density will be assessed using the OCT

Intervention type: DEVICE
Intervention: Laser Speckle Flowgraphy (LSFG)
Description: Normalized blur and Relative flow volume will be assessed using the LSFG

Intervention type: DEVICE
Intervention: Laser Speckle Flowgraphy (LSFG)
Description: Normalized blur and Relative flow volume will be assessed using the LSFG

Intervention type: DEVICE
Intervention: Laser Speckle Flowgraphy (LSFG)
Description: Normalized blur and Relative flow volume will be assessed using the LSFG

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics and Metabolites in Plasma, tear fluid and finger sweat
Description: Proteomics and Metabolites in Plasma, tear fluid and finger sweat will be assessed using a Blooddraw, filter paper and Schirmer-test

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics and Metabolites in Plasma, tear fluid and finger sweat
Description: Proteomics and Metabolites in Plasma, tear fluid and finger sweat will be assessed using a Blooddraw, filter paper and Schirmer-test

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics and Metabolites in Plasma, tear fluid and finger sweat
Description: Proteomics and Metabolites in Plasma, tear fluid and finger sweat will be assessed using a Blooddraw, filter paper and Schirmer-test
Study: NCT05315024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluarix Tetra
Description: Fluarix Tetra

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluarix Tetra
Description: Fluarix Tetra

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluarix Tetra
Description: Fluarix Tetra

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod cream
Description: Imiquimod cream
Study: NCT06177015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darolutamide continuous
Description: standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide intermittent
Description: experimental group
Study: NCT05648123

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy
Description: Supportive psychotherapy is a treatment that uses direct measures to ameliorate symptoms and to maintain, restore or improve self-esteem, ego function, and adaptive skills

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Psychotherapy
Description: Supportive psychotherapy is a treatment that uses direct measures to ameliorate symptoms and to maintain, restore or improve self-esteem, ego function, and adaptive skills
Study: NCT05187494

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional local palatine injection
Description: Conventional palatal injection with anesthetic (lidocaine HCL2% with Epinephrine 1:80000, Korea) Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA cream only
Description: Emla cream will be applied at a distance of 1 mm from the palatine gingival edge by cotton buds for 3 minutes within the application area 14\*14 mm and the mouth will be open throughout the procedure and the saliva will be controlled by a saliva absorbent. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemical permeability enhancer DMSO with EMLA cream
Description: Adding 10 g of EMLA cream 5%, 1,026 g of DMSO 100% and it will be applied with cotton bud for a period of 3 minutes while the child is opening his mouth and the saliva is controlled by saliva absorbent. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral patches with EMLA Cream
Description: EMLA cream 5% will be applied at a distance of 1 mm from the palatal gingival edge using an oral patch 14\*14 mm for 3 minutes and the Mouth will be closed throughout the procedure. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micro-needle patches dissolved with EMLA Cream
Description: EMLA cream 5% will be applied at a distance of 1 mm from the palatal gingival edge using an micro-needle patch 14\*14 mm, 0,25 micron for 3 minutes and the Mouth will be closed throughout the procedure. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.
Study: NCT06113172

Intervention type: OTHER
Group type: OTHER
Intervention: Hip flexion
Description: during the delay phase, the patients are asked to bend their knee in order to achieve the maximum degree of hip flexion

Intervention type: OTHER
Group type: OTHER
Intervention: Hip flexion
Description: during the delay phase, the patients are asked to bend their knee in order to achieve the maximum degree of hip flexion
Study: NCT05166486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calisthenic exercise
Description: Exercises involving major muscle groups will be given. Before starting the calisthenic exercises, they will be asked to perform 10 repetitive warm-ups and breathing exercises. The intensity of the calisthenic exercises will be adjusted on a weekly basis.~Calisthenic exercises are repeated 10-15 times in the first and second weeks; third and fourth weeks 15-20 repetitive; In the five, six, seven and eight weeks, it will be done with 25-30 repetitions.~Patients will be asked to keep an exercise diary and weekly follow-ups will be made over the phone.~Within eight weeks, each patient will come for control twice a month and will be asked to perform the exercises individually under the supervision of a physiotherapist. Patients will be asked to do the exercises three times a week for 8 weeks.
Study: NCT04672031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycemic Targets
Description: The intervention is glycemic targets that are lower than those currently recommended by ADA and ACOG: fasting ≤80 mg/dL, pre-prandial ≤80 mg/dL, and 1-hour postprandial ≤110 mg/dL instead of fasting ≤95 mg/dL, pre-prandial ≤95 mg/dL, and 1-hour postprandial ≤140 mg/dL.
Study: NCT06049251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELDOA exercises
Description: The patients will be asked to sit down on a floor in upright position and keep their legs apart and knees semi-flexed, feet in outward and upward position, knees constantly pushing downwards, straight lower back, raise arms with palms facing upward, and chin should be pulled back.~ELDOA stretch for L5-S1 level Patients will be asked to lay on floor and flatten and bring their legs up and straight with the support of wall, straight knees and keep distance between them, connect their toes, raise arm and externally rotate with wrist extension than press their heels and palms out.~ELDOA exercises will be performed with 2 sets of 5 repetitions with 45 second hold and15 sec rest between each set once a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar SNAGS and motor control exercises
Description: The patient will be seated and his pelvis will be stabilized with belt at the level of the anterior superior iliac spine while the SNAGs are administered. The ulnar aspect of the therapist's hand will be placed over the spinous processes of the affected segment's superior vertebrae, for flexion glide and inferior vertebrae for extension glide respectively. A passive glide will be applied and kept up until the patient finished a full movement arc. The glides will be given for six repetitions for three sets every session. Glide can be given unilateral for other movements.~Motor Control Exercises:~Exercise training with 7sec Hold and 10 reps
Study: NCT06296966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSJ-110
Description: ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ophthalmic solution
Study: NCT05658978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular training
Description: Neuromuscular training Length: 12 weeks; Training duration: 90 minutes; Intensity: 70-95%; 3 days per week. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes; Rest: 30 seconds rest between exercises and 1-minute rest between sets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The Control group continues previous regular exercises for 12 weeks with a duration of 90 minutes and three days per week.
Study: NCT05545358

Intervention type: OTHER
Intervention: Questionnaires
Description: Short-Form McGill Pain Questionnaire (SF-MPQ) Pain Disability Index (PDI) Prosthesis Evaluation Questionnaire (PEQ) Psychological Inflexibility to Pain Scale (PIPS) Chronic Pain Acceptance Questionnaire (CPAQ) Cognitive Difficulties Scale (CDS) Amputee Body Image Scale (ABIS) Trinity Amputation and Prosthesis Experience Scales (TAPES) Pain Catastrophizing Scale (PCS) Hospital Anxiety and Depression Scale (HAD) Credibility/Expectancy Questionnaire (CEQ) Short-Form Edinburgh Handedness Inventory (SF-EHI) Patient's Global Impression of Change (PGIC)

Intervention type: OTHER
Intervention: Questionnaires
Description: Short-Form McGill Pain Questionnaire (SF-MPQ) Pain Disability Index (PDI) Prosthesis Evaluation Questionnaire (PEQ) Psychological Inflexibility to Pain Scale (PIPS) Chronic Pain Acceptance Questionnaire (CPAQ) Cognitive Difficulties Scale (CDS) Amputee Body Image Scale (ABIS) Trinity Amputation and Prosthesis Experience Scales (TAPES) Pain Catastrophizing Scale (PCS) Hospital Anxiety and Depression Scale (HAD) Credibility/Expectancy Questionnaire (CEQ) Short-Form Edinburgh Handedness Inventory (SF-EHI) Patient's Global Impression of Change (PGIC)

Intervention type: DEVICE
Intervention: Brain and Spinal Cord functional Magnetic Resonance Imaging
Description: Brain and Spinal Cord functional Magnetic Resonance Imaging

Intervention type: DEVICE
Intervention: Brain and Spinal Cord functional Magnetic Resonance Imaging
Description: Brain and Spinal Cord functional Magnetic Resonance Imaging

Intervention type: DEVICE
Intervention: Brain and Spinal Cord functional Magnetic Resonance Imaging
Description: Brain and Spinal Cord functional Magnetic Resonance Imaging

Intervention type: OTHER
Intervention: Proprioceptive training
Description: Proprioceptive muscular training via a mechanical vibration of low amplitude and frequency between 60 and 80 Hz applied to the tendons.

Intervention type: OTHER
Intervention: Proprioceptive training
Description: Proprioceptive muscular training via a mechanical vibration of low amplitude and frequency between 60 and 80 Hz applied to the tendons.
Study: NCT05522985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triprilimab combined with TP
Description: Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triprilimab combined with TP
Description: Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
Study: NCT06349655

Intervention type: DRUG
Intervention: Azvudine
Description: Antiviral drug

Intervention type: DRUG
Intervention: Paxlovid
Description: Antiviral drug